Heartland Advisors Inc. Sells 48,175 Shares of Haemonetics Co. (NYSE:HAE)

Heartland Advisors Inc. lessened its stake in shares of Haemonetics Co. (NYSE:HAE) by 34.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 92,923 shares of the medical instruments supplier’s stock after selling 48,175 shares during the period. Heartland Advisors Inc.’s holdings in Haemonetics were worth $7,255,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Whittier Trust Co. bought a new stake in Haemonetics during the 4th quarter valued at $62,000. Parkside Financial Bank & Trust raised its holdings in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 240 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after acquiring an additional 1,826 shares in the last quarter. KBC Group NV lifted its stake in Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares during the period. Finally, iSAM Funds UK Ltd bought a new position in Haemonetics during the 3rd quarter worth about $204,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 1.8 %

HAE stock opened at $63.03 on Friday. The stock has a market capitalization of $3.17 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The firm has a 50 day moving average of $66.05 and a 200 day moving average of $74.68.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on HAE. Needham & Company LLC lowered their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. JMP Securities dropped their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. Barrington Research reduced their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.